Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation
Introduction Interferon beta (IFN beta) preparations are an established group of drugs used
for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied …
for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied …
Dynamic evolution of humoral and T-cell specific immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis followed until the booster dose
This study characterizes antibody and T-cell immune responses over time until the booster
dose of COronaVIrus Disease 2019 (COVID-19) vaccines in patients with multiple sclerosis …
dose of COronaVIrus Disease 2019 (COVID-19) vaccines in patients with multiple sclerosis …
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 …
A Elgenidy, NN Abdelhalim, MAM Al-Kurdi… - Frontiers in …, 2024 - frontiersin.org
Background Recent years have seen the emergence of disease-modifying therapies in
multiple sclerosis (MS), such as anti-cluster of differentiation 20 (anti-CD20) monoclonal …
multiple sclerosis (MS), such as anti-cluster of differentiation 20 (anti-CD20) monoclonal …
Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections
A Langer-Gould, BH Li, JB Smith… - Neurology …, 2024 - AAN Enterprises
Background and Objectives B-cell–depleting therapies increase the risk of infections and
hypogammaglobulinemia. These relationships are poorly understood. The objectives of …
hypogammaglobulinemia. These relationships are poorly understood. The objectives of …
Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing–similar clinical efficacy with decreased immunoglobulin M deficiency rates
T Rempe, A Elfasi, E Rodriguez, M Vasquez… - Multiple Sclerosis and …, 2023 - Elsevier
Background Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody used in
treatment of multiple sclerosis. The standard dosing (SD) regimen consists of OCR …
treatment of multiple sclerosis. The standard dosing (SD) regimen consists of OCR …
[HTML][HTML] Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab
B cell depletion by the anti-CD20 antibody ocrelizumab is effective in relapsing-remitting
(RR) and primary progressive (PP) multiple sclerosis (MS). We investigated immunological …
(RR) and primary progressive (PP) multiple sclerosis (MS). We investigated immunological …
Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice
AG Vakrakou, ME Brinia, A Alexaki… - International …, 2023 - Elsevier
The expanded treatment landscape in relapsing-remitting multiple sclerosis (MS) has
resulted in highly effective treatment options and complexity in managing disease-or drug …
resulted in highly effective treatment options and complexity in managing disease-or drug …
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis
I Monteiro, V Nicolella, M Fiorenza, F Novarella… - Journal of …, 2024 - Springer
Objective The wearing-off phenomenon is common in people with multiple sclerosis (MS)
treated with ocrelizumab. We aim to evaluate the presence and severity of wearing-off to …
treated with ocrelizumab. We aim to evaluate the presence and severity of wearing-off to …
Clinical efficacy of anti-CD20 antibodies in neurological and neuromuscular diseases
Y Fan, T Chen, Y Liu, B Peng - Resistance to Anti-Cd20 Antibodies and …, 2024 - Elsevier
Abstract Cluster of differentiation 20 (CD20) is an integral membrane protein expressed
mainly on different developmental stages of B lymphocytes and rarely on T lymphocytes …
mainly on different developmental stages of B lymphocytes and rarely on T lymphocytes …
[引用][C] Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal
WCS Cho - 2023 - Elsevier